In Phase C, members will acquire ABBV-744 and oral navitoclax. In Segment D, participants will receive ABBV-744 and ruxolitinib. Participants will acquire treatment until finally disease progression or the members are not able to tolerate the study drugs. Celastrol was discovered being a Myb inhibitor that suppressed C/EBPβ activity and https://abbv-744-in-clinical-tria70134.bligblogging.com/32649372/5-essential-elements-for-abbv-744-in-clinical-trials-for-non-small-cell-lung-cancer-nsclc